Daniel Loeb Catalent, Inc. Transaction History

Third Point LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$45.44 - $74.26 $9.09 Million - $14.9 Million	200,000 New	200,000 $13.1 Million
Q2 2022 Aug 15, 2022	SELL	$87.2 - $114.05 $118 Million - $154 Million	-1,350,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$94.19 - $124.49 $54.2 Million - $71.6 Million	-575,000 Reduced 29.87%	1,350,000 $150 Million
Q4 2021 Feb 14, 2022	BUY	$119.57 - $139.07 $65.8 Million - $76.5 Million	550,000 Added 40.0%	1,925,000 $246 Million
Q3 2021 Nov 15, 2021	BUY	$109.17 - $142.35 $16.4 Million - $21.4 Million	150,000 Added 12.24%	1,375,000 $183 Million
Q4 2020 Feb 16, 2021	BUY	$85.88 - $105.36 $105 Million - $129 Million	1,225,000 New	1,225,000 $127 Million

514

149M

575K

2.03M

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $11B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

Get notified when there are updates to the investment portfolio of Third Point LLC, based on Form 13F filings with the SEC.

Stay updated on Third Point LLC and Daniel Loeb with notifications on news.